Takara Bio Europe AB and PanCryos have announced licensing agreement to enable development of cell-based therapy for diabetes – SelectScience

Takara Bio Europe AB (TBEAB) and PanCryos have announced that they have reached a licensing agreement surrounding TBEABs clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucose-responsive beta cells and is one of several customers in TBEABs new out-licensing program, which enables industrial partners to use the clinical-grade hES cells to develop and commercialize breakthrough cell therapy products for previously unmet indications.

Jacqueline Ameri, CEO of PanCryos said, "We are very hopeful that our extensive scientific and industry expertise, combined with TBEABs expertise in clinical-grade hES cell production, will put us in a position to take the crucial next step in the development of our best-in-class, commercially sustainable PanINSULA cell therapy for type 1 diabetes."

This announcement comes following TBEABs successful establishment of a new clinical-grade hES cell line. The derivation work and scale-up were conducted with feeder-free and xeno-free culture conditions under a manufacturing license granted by the Swedish MPA at TBEABs state-of-the-art GMP manufacturing facility in Gteberg, Sweden.

"To our knowledge, this is the first human ES cell line that was derived under GMP conditions based on starting material sourced from prion-free countries, and where the donors were tested within 7 days of the retrieval of the starting material according to FDAs requirement," said Kristina Runeberg, Site Head and Senior Director, Business Development at TBEAB. "We take pride in our rigorous quality and safety standards, and our customers know they can rely on us for high-quality, safe starting material for their cell therapy development."

The out-licensing program is the newest addition to TBEABs ever-expanding portfolio of solutions, including services and GMP-grade media, that support cell therapy applications in Europe. These products and services are also available in North America through TBEABs affiliate Takara Bio USA, Inc.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

The rest is here:

Takara Bio Europe AB and PanCryos have announced licensing agreement to enable development of cell-based therapy for diabetes - SelectScience